Trial · NCT00413062
Results by group218
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 218
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index) | NOMAC-E2 | Overall group | 1.754 | 95% Confidence Interval 0.9061 to 3.0632 | Pregnancies per 100 woman years |
| Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index) | DRSP-EE | Overall group | 3.005 | 95% Confidence Interval 1.2082 to 6.1917 | Pregnancies per 100 woman years |
| Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index) | NOMAC-E2 | =<35 years old (n=1158; n=378) | 1.963 | 95% Confidence Interval 0.9798 to 3.5119 | Pregnancies per 100 woman years |
| Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index) | DRSP-EE | =<35 years old (n=1158; n=378) | 3.092 | 95% Confidence Interval 1.1347 to 6.7299 | Pregnancies per 100 woman years |
| Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index) | NOMAC-E2 | >35 years old (n=212; n=66) | 0.807 | 95% Confidence Interval 0.0204 to 4.4977 | Pregnancies per 100 woman years |
| Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index) | DRSP-EE | >35 years old (n=212; n=66) | 2.572 | 95% Confidence Interval 0.0651 to 14.33 | Pregnancies per 100 woman years |
| Number of Participants With an Occurrence of Breakthrough Bleeding/Spotting | NOMAC-E2 | Cycle 1 (n=1202 NOMAC-E2; n=398 DRSP-EE) | 370 | participants | |
| Number of Participants With an Occurrence of Breakthrough Bleeding/Spotting | DRSP-EE | Cycle 1 (n=1202 NOMAC-E2; n=398 DRSP-EE) | 84 | participants | |
| Number of Participants With an Occurrence of Breakthrough Bleeding/Spotting | NOMAC-E2 | Cycle 2 (n=950 NOMAC-E2; n=308 DRSP-EE) | 243 | participants | |
| Number of Participants With an Occurrence of Breakthrough Bleeding/Spotting | DRSP-EE | Cycle 2 (n=950 NOMAC-E2; n=308 DRSP-EE) | 55 | participants | |
| Number of Participants With an Occurrence of Breakthrough Bleeding/Spotting | NOMAC-E2 | Cycle 3 (n=812 NOMAC-E2; n=256 DRSP-EE) | 196 | participants | |
| Number of Participants With an Occurrence of Breakthrough Bleeding/Spotting | DRSP-EE | Cycle 3 (n=812 NOMAC-E2; n=256 DRSP-EE) | 40 | participants | |
| Number of Participants With an Occurrence of Breakthrough Bleeding/Spotting | NOMAC-E2 | Cycle 4 (n=739 NOMAC-E2; n=236 DRSP-EE) | 152 | participants | |
| Number of Participants With an Occurrence of Breakthrough Bleeding/Spotting | DRSP-EE | Cycle 4 (n=739 NOMAC-E2; n=236 DRSP-EE) | 34 | participants | |
| Number of Participants With an Occurrence of Breakthrough Bleeding/Spotting | NOMAC-E2 | Cycle 5 (n=671 NOMAC-E2; n=229 DRSP-EE) | 139 | participants | |
| Number of Participants With an Occurrence of Breakthrough Bleeding/Spotting | DRSP-EE | Cycle 5 (n=671 NOMAC-E2; n=229 DRSP-EE) | 29 | participants | |
| Number of Participants With an Occurrence of Breakthrough Bleeding/Spotting | NOMAC-E2 | Cycle 6 (n=628 NOMAC-E2; n=207 DRSP-EE) | 125 | participants | |
| Number of Participants With an Occurrence of Breakthrough Bleeding/Spotting | DRSP-EE | Cycle 6 (n=628 NOMAC-E2; n=207 DRSP-EE) | 18 | participants | |
| Number of Participants With an Occurrence of Breakthrough Bleeding/Spotting | NOMAC-E2 | Cycle 7 (n=565 NOMAC-E2; n=196 DRSP-EE) | 104 | participants | |
| Number of Participants With an Occurrence of Breakthrough Bleeding/Spotting | DRSP-EE | Cycle 7 (n=565 NOMAC-E2; n=196 DRSP-EE) | 25 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00413062/results